RxDoctor Payments Data

Frank Ashburn, MD

Glaucoma Specialist · Washington, DCNPI 1538426051

Payments from drug & device makers

$4,545in general payments, 2019–2025

Across 102 payments — averaging $44.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alcon$481
  • Tarsus Pharmaceuticals, Inc.$303
  • Sun Pharmaceutical Industries Inc.$215
  • Astellas Pharma US Inc$211
  • Bausch & Lomb Americas Inc.$184
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,545100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$554,560
Medicare patients
1,417
Services billed
3,853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine39$60,076
XiidraLifitegrast16$27,241
LumiganBimatoprost46$24,993
VyzultaLatanoprostene Bunod24$17,044
Restasis MultidoseCyclosporine11$9,740
RhopressaNetarsudil Mesylate12$7,849
Cyclosporine18$7,316
AzoptBrinzolamide14$6,859
Travoprost38$6,359
TafluprostTafluprost/Pf12$5,613
Latanoprost421$4,982
Timolol MaleateTimolol Maleate/Pf11$4,800
Tobramycin-DexamethasoneTobramycin/Dexamethasone101$4,763
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol30$4,124
Brimonidine Tartrate53$4,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose$1,668$94,80896 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$184$44,28540 claims
Aerie Pharmaceuticals, Inc.Rhopressa$131$7,84912 claims
AlconAzopt$481$6,85914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Washington

Where these figures come from

Is this you, or does something look wrong? →